Amyloid-forming properties of human apolipoproteins: Sequence analyses and structural insights

Advances in Experimental Medicine and Biology

Volumn 855, Issue , 2015, Pages 175-211

  Das, Madhurima ^a   Gursky, Olga ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis and Alzheimer s disease; Atomic protein structure; Lipid transport; Sequence based prediction algorithms; Systemic amyloidosis

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; LIPOPROTEIN; SERUM AMYLOID A; AMYLOID;

ALPHA HELIX; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOIDOSIS; ARTICLE; ATHEROSCLEROSIS; BETA SHEET; BIOINFORMATICS; HUMAN; HYDROPHOBICITY; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; AMYLOID; APOLIPOPROTEINS; HUMANS; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN CONFORMATION;

EID: 84936806267     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-17344-3_8     Document Type: Article

References (187)

1. Acharya P, Segall ML, Zaiou M, Morrow J, Weisgraber KH, Phillips MC, Lund-Katz S, Snow J (2002) Comparison of the stabilities and unfolding pathways of human apolipoprotein E isoforms by differential scanning calorimetry and circular dichroism. Biochim Biophys Acta 1584(1):9–19
2. Adachi E, Nakajima H, Mizuguchi C, Dhanasekaran P, Kawashima H, Nagao K, Akaji K, Lund-Katz S, Phillips MC, Saito H (2013) Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation. J Biol Chem 288:2848–2856
3. Adachi E, Kosaka A, Tsuji K, Mizuguchi C, Kawashima H, Shigenaga A, Nagao K, Akaji K, Otaka A, Saito H (2014) The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils. FEBS Lett 588(3):389–394
4. Arciello A, De Marco N, Del Giudice R, Guglielmi F, Pucci P, Relini A, Monti DM, Piccoli R (2011) Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells. J Cell Mol Med 15:2652–2663
5. Asatryan L, Hamilton RT, Isas JM, Hwang J, Kayed R, Sevanian A (2005) LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. J Lipid Res 46(1):115–122
6. Banach M (2014) Editorial: current research, knowledge and controversies on high density lipoprotein. Curr Med Chem 21(25):2853–2854
7. Bancells C, Villegas S, Blanco FJ, Benitez S, Gallego I, Beloki L, Perez-Cuellar M, Ordonez-Llanos J, Sanchez-Quesada JL (2010) Aggregated electronegative low-density lipoprotein in human plasma shows high tendency to phospholipolysis and particle fusion. J Biol Chem 285(42):32425–32435
8. Beckstead JA, Wong K, Gupta V, Wan CP, Cook VR, Weinberg RB, Weers PM, Ryan RO (2007) The C terminus of apolipoprotein A-V modulates lipid-binding activity. J Biol Chem 282(21):15484–15489
9. Benson MD, Liepnieks JJ, Yazaki M, Yamashita T, Hamidi Asl K, Guenther B, Kluve-Beckerman B (2001) A new human hereditary amyloidosis: the result of a stopcodon mutation in the apolipoprotein AII gene. Genomics 72(3):272–277
10. Benson MD, Kalopissis AD, Charbert M, Liepnieks JJ, Kluve-Beckerman B (2011) A transgenic mouse model of human systemic ApoA-II amyloidosis. Amyloid 18(Suppl 1):32–33
11. Bergström J, Murphy CL, Weiss DT, Solomon A, Sletten K, Hellman U, Westermark P (2004) Two different types of amyloid deposits – apolipoprotein A-IV and transthyretin – in a patient with systemic amyloidosis. Lab Invest 84(8):981–988
12. Borhani DW, Rogers DP, Engler JA, Brouillette CG (1997) Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci U S A 94(23):12291–12296
13. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW (2001) Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta 1531(1–2):4–46
14. Brunelli R, De Spirito M, Mei G, Papi M, Perrone G, Stefanutti C, Parasassi T (2014) Misfolding of apoprotein B-100, LDL aggregation and 17-β-estradiol in atherogenesis. Curr Med Chem 21(20):2276–2283
15. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G (1998) Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 139(2):205–222
16. Castelli WP, Anderson K, Wilson PW, Levy D (1992) Lipids and risk of coronary heart disease. The Framingham study. Ann Epidemiol 2(1–2):23–28
17. Castillo V, Ventura S (2009) Amyloidogenic regions and interaction surfaces overlap in globular proteins related to conformational diseases. PLoS Comput Biol 5(8):e1000476
18. Cavigiolio G, Geier EG, Shao B, Heinecke JW, Oda MN (2010) Exchange of apolipoprotein A-I between lipidassociated and lipid-free states: a potential target or oxidative generation of dysfunctional high density lipoproteins. J Biol Chem 285:18847–18857
19. Chan GK, Witkowski A, Gantz DL, Zhang TO, Zanni MT, Jayaraman S, Cavigiolio G (2015) Myeloperoxidasemediated methionine oxidation promotes an amyloidogenic outcome for apolipoprotein A-I. J Biol Chem 290(17):10958–10971
20. Chen J, Li Q, Wang J (2011) Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci U S A 108(36):14813–14818
21. Chetty PS, Mayne L, Lund-Katz S, Stranz D, Englander SW, Phillips MC (2009) Helical structure and stability in human apolipoprotein A-I by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci U S A 106:19005–19010
22. Chetty PS, Ohshiro M, Saito H, Dhanasekaran P, Lund- Katz S, Mayne L, Englander W, Phillips MC (2012) Effects of the Iowa and Milano mutations on apolipoprotein A-I structure and dynamics determined by hydrogen exchange and mass spectrometry. Biochemistry 51:8993–9001
23. Chiti F, Dobson CM (2009) Amyloid formation by globular proteins under native conditions. Nat Chem Biol 5(1):15–22
24. Cho HS, Hyman BT, Greenberg SM, Rebeck GW (2001) Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation. J Neuropathol Exp Neurol 60:342–349
25. Conchillo-Solé O, de Groot NS, Avilés FX, Vendrell J, Daura X, Ventura S (2007) AGGRESCAN: a server for the prediction and evaluation of “hot spots” of aggregation in polypeptides. BMC Bioinformatics 8:65
26. Cui Y, Huang M, He Y, Zhang S, Luo Y (2011) Genetic ablation of apolipoprotein A-IV accelerates Alzheimer’s disease pathogenesis in a mouse model. Am J Pathol 178:1298–1308
27. Das M, Jayaraman S, Mei X, Atkinson D, Gursky O (2014) Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing: a common mechanism of apoA-I misfolding in familial amyloidosis and atherosclerosis. FEBS J 281(11):2525–2542
28. De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB (1982) Serum amyloid-A protein concentration in infl ammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 2(8292):231–234
29. de Messieres M, Huang RK, He Y, Lee JC (2014) Amyloid triangles, squares, and loops of apolipoprotein C-III. Biochemistry 53(20):3261–3263
30. Deng X, Morris J, Dressmen J, Tubb MR, Tso P, Jerome WG, Davidson WS, Thompson TB (2012) The structure of dimeric apolipoprotein A-IV and its mechanism of self-association. Structure 20(5):767–779
31. Deng X, Morris J, Chaton C, Schröder GF, Davidson WS, Thompson TB (2013) Small-angle X-ray scattering of apolipoprotein A-IV reveals the importance of its termini for structural stability. J Biol Chem 288(7):4854–4866
32. Deng X, Walker RG, Morris J, Davidson WS, Thompson TB (2015) Role of conserved proline residues in human apolipoprotein A-IV structure and function. J Biol Chem 290(17):10689–10702
33. Derebe MG, Zlatkov CM, Gattu S, Ruhn KA, Vaishnava S, Diehl GE, MacMillan JB, Williams NS, Hooper LV (2014) Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection. Elife 3:e03206
34. Der-Sarkissian A, Jao CC, Chen J, Langen R (2003) Structural organization of α-synuclein fibrils studied by site-directed spin labeling. J Biol Chem 278:37530–37535
35. Egashira M, Takase H, Yamamoto I, Tanaka M, Saito H (2011) Identification of regions responsible for heparin- induced amyloidogenesis of human serum amyloid A using its fragment peptides. Arch Biochem Biophys 511(1–2):101–1016
36. Eklund KK, Niemi K, Kovanen PT (2012) Immune functions of serum amyloid A. Crit Rev Immunol 32(4):335–348
37. Fernandez-Escamilla AM, Rousseaux F, Schymkowitz J, Serrano L (2004) Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22:1302–1306
38. Galzitskaya OV, Garbuzynskiy SG, Lobanov MV (2006) Prediction of amyloidogenic and disordered regions in protein chains. PLoS Comput Biol 2(12):e177
39. Gangabadage CS, Zdunek J, Tessari M, Nilsson S, Olivecrona G, Wijmenga SS (2008) Structure and dynamics of human apolipoprotein CIII. J Biol Chem 283(25):17416–17427
40. Gao X, Yuan S, Jayaraman S, Gursky O (2012) Effect of apolipoprotein A-II on the structure and stability of human high-density lipoprotein: implications for the role of apoA-II in HDL metabolism. Biochemistry 51(23):4633–4641
41. Garbuzynskiy SO, Lobanov MY, Galzitskaya OV (2010) FoldAmyloid: a method of prediction of amyloidogenic regions from protein sequence. Bioinformatics 26(3):326–332
42. Getz GS, Reardon CA (2009) Apoprotein E as a lipid transport and signaling protein in the blood, liver and artery wall. J Lipid Res 50:S156–S161
43. Gillard BK, Lin HY, Massey JB, Pownall HJ (2009) Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta 1791:1125–1132
44. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358(9275): 24–29
45. Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O’Grady J, Heaton ND, Pepys MB, Hawkins PN (2006) Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant 6(10):2342–2347
46. Goldstein JL, Brown MS (1976) The LDL pathway in human fibroblasts: a receptor-mediated mechanism for the regulation of cholesterol metabolism. Curr Top Cell Regul 11:147–181
47. Goldstein JL, Brown MS (1992) Lipoprotein receptors and the control of plasma LDL cholesterol levels. Eur Heart J 13(Suppl B):34–36
48. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA (1989) High-density lipoprotein cholesterol and cardiovascular disease. Circulation 79:8–15
49. Green PH, Glickman RM, Riley JW, Quinet E (1980) Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest 65:911–919
50. Guha M, England CO, Herscovitz H, Gursky O (2007) Thermal transitions in human very low-density lipoprotein: fusion, rupture and dissociation of HDL-like particles. Biochemistry 46(20):6043–6049
51. Guha M, Gao X, Jayaraman S, Gursky O (2008) Structural stability and functional remodeling of high-density lipoproteins: the importance of being disordered. Biochemistry 47(44):11393–11397
52. Gursky O (2005) Apolipoprotein structure and dynamics. Curr Opin Lipidol 16(3):287–294
53. Gursky O (2013) Crystal structure of Δ(185–243)apoA-I suggests a mechanistic framework for the protein adaptation to the changing lipid load in good cholesterol: from fl atland to sphereland via double belt, belt buckle, double hairpin and trefoil/tetrafoil. J Mol Biol 425:1–16
54. Gursky O (2014) Hot spots in apolipoprotein A-II misfolding and amyloidosis in mice and men. FEBS Lett 588(6):845–850
55. Gursky O, Atkinson D (1996a) Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Proc Natl Acad Sci U S A 93:2991–2995
56. Gursky O, Atkinson D (1996b) High- and low- temperature unfolding of human high-density apolipoprotein A-2. Protein Sci 5(9):1874–1882
57. Gursky O, Atkinson D (1998) Thermodynamic analysis of human plasma apolipoprotein C-1: high- temperature unfolding and low-temperature oligomer dissociation. Biochemistry 37(5):1283–1291
58. Gursky O, Mei X, Atkinson D (2012) Crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on the amyloid formation by the N-terminal segment. Biochemistry 51(1):10–18
59. Hamodrakas SJ, Liappa C, Iconomidou VA (2007) Consensus prediction of amyloidogenic determinants in amyloid-forming proteins. Int J Biol Macromol 41:295–300
60. Hatters DM, Howlett GJ (2002) The structural basis for amyloid formation by plasma apolipoproteins: a review. Eur Biophys J 31(1):2–8
61. Hatters DM, Budamagunta MS, Voss JC, Weisgraber KH (2005) Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms. J Biol Chem 280(40):34288–34295
62. Hatters DM, Zhong N, Rutenber E, Weisgraber KH (2006) Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol 361(5):932–944
63. Hauser PS, Ryan RO (2013) Impact of apolipoprotein E on Alzheimer’s disease. Curr Alzheimer Res 10(8): 809–817
64. Hauser PS, Narayanaswami V, Ryan RO (2011) Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res 50(1):62–74
65. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2(3):a006312
66. Howlett GJ, Moore KJ (2006) Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol 17(5):541–547
67. Huang Y (2010) Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol 21(4):337–345
68. Jayaraman S, Gantz DL, Gursky O (2005a) Kinetic stabilization and fusion of discoidal lipoproteins containing human apoA-2 and DMPC: comparison with apoA-1 and apoC-1. Biophys J 88(4):2907–2918
69. Jayaraman S, Gantz DL, Gursky O (2005b) Structural basis for thermal stability of human low-density lipoprotein. Biochemistry 44(10):3965–3971
70. Jayaraman S, Gantz DL, Gursky O (2006) Effects of salt on the thermal stability of human plasma high-density lipoprotein. Biochemistry 45(14):4620–4628
71. Jayaraman S, Gantz DL, Gursky O (2007) Effects of oxidation on the structure and stability of human lowdensity lipoprotein. Biochemistry 46(19):5790–5797
72. Jayaraman S, Cavigiolio G, Gursky O (2012) Folded functional lipid-poor apolipoprotein A-I obtained by heating of high-density lipoproteins: relevance to HDL biogenesis. Biochem J 442(3):703–712
73. Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19(3):472–484
74. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61(7):906–921
75. Kim C, Choi J, Lee SJ, Welsh WJ, Yoon S (2009) NetCSSP: web application for predicting chameleon sequences and amyloid fibril formation. Nucleic Acids Res 37:W469–W473
76. Kingwell BA, Chapman MJ, Kontush A, Miller NE (2014) HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov 13(6):445–464
77. Krauss RM (1998) Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 81(4A):13B–17B
78. Kumar V, Butcher SJ, Öörni K, Engelhardt P, Heikkonen J, Kaski K, Ala-Korpela M, Kovanen PT (2011) Three-dimensional cryoEM reconstruction of native LDL particles to 16Å resolution at physiological body temperature. PLoS ONE 6:e18841
79. Ladu MJ, Reardon C, Van Eldik L, Fagan AM, Bu G, Holtzman D, Getz GS (2000) Lipoproteins in the central nervous system. Ann N Y Acad Sci 903:167–175
80. Lamarche B, Rashid S, Lewis GF (1999) HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 286(1–2):145–161
81. Lane-Donovan C, Philips GT, Herz J (2014) More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron 83(4):771–787
82. Lepedda AJ, Cigliano A, Cherchi GM, Spirito R, Maggioni M, Carta F, Turrini F, Edelstein C, Scanu AM, Formato M (2009) A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 203(1):112–118
83. Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L (2010) Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinfl ammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem 285(47):36958–36968
84. Li WH, Tanimura M, Luo CC, Datta S, Chan L (1988) The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res 29(3):245–271
85. Liu Y, Atkinson D (2011) Immuno-electron cryomicroscopy imaging reveals a looped topology of apoB at the surface of human LDL. J Lipid Res 52(6):1111–1116
86. Lu M, Gursky O (2013) Aggregation and fusion of lowdensity lipoproteins in vivo and in vitro. Biomol Concepts. doi: 10.155/bmc-2013-0016
87. Lu M, Gantz DL, Herscovitz H, Gursky O (2012) Kinetic analysis of thermal stability of human low-density lipoproteins: model for LDL fusion in atherogenesis. J Lipid Res 53(10):2175–2185
88. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R (2013) Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 154(6):1257–1268
89. Lu J, Yu Y, Zhu I, Cheng Y, Sun PD (2014) Structural mechanism of serum amyloid A-mediated infl ammatory amyloidosis. Proc Natl Acad Sci U S A 111(14):5189–5194
90. Lv G, Kumar A, Giller K, Orcellet ML, Riedel D, Fernández CO, Becker S, Lange A (2012) Structural comparison of mouse and human α synuclein amyloid fibrils by solid-state NMR. J Mol Biol 420(1–2):99–111
91. Lyssenko NN, Hata M, Dhanasekaran P, Nickel M, Nguyen D, Chetty PS, Saito H, Lund-Katz S, Phillips MC (2012) Infl uence of C-terminal α-helix hydrophobicity and aromatic amino acid content on apolipoprotein A-I functionality. Biochim Biophys Acta 1821(3):456–463
92. Ma J, Yee A, Brewer HB Jr, Das S, Potter H (1994) Amyloid-associated proteins alpha 1- antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372(6501):92–94
93. MacRaild CA, Hatters DM, Howlett GJ, Gooley PR (2001) NMR structure of human apolipoprotein C-II in the presence of sodium dodecyl sulfate. Biochemistry 40(18):5414–5421
94. MacRaild CA, Howlett GJ, Gooley PR (2004) The structure and interactions of human apolipoprotein C-II in dodecyl phosphocholine. Biochemistry 43(25):8084–8093
95. Magy N, Liepnieks JJ, Yazaki M, Kluve-Beckerman B, Benson MD (2003) Renal transplantation for apolipoprotein AII amyloidosis. Amyloid 10(4):224–228
96. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH (1984) Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 25(12):1277–1294
97. Mahley RW, Weisgraber K, Huang Y (2009) Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res 50:S183–S18
98. Maiga SF, Kalopissis AD, Chabert M (2014) Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes. Biochimie 96:56–66
99. Marchesi M, Parolini C, Valetti C, Mangione P, Obici L, Giorgetti S, Raimondi S, Donadei S, Gregorini G, Merlini G, Stoppini M, Chiesa G, Bellotti V (2011) The intracellular quality control system downregulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease. Biochim Biophys Acta 1812(1):87–93
100. Margittai M, Langen R (2008) Fibrils with parallel inregister structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy. Rev Biophys 41(3–4):265–297
101. Mauldin K, Lee BL, Oleszczuk M, Sykes BD, Ryan RO (2010) The carboxyl-terminal segment of apolipoprotein A-V undergoes a lipid-induced conformational change. Biochemistry 49(23):4821–4826
102. Maurer-Stroh S, Debulpaep M, Kuemmerer N, Lopez de la Paz M, Martins IC, Reumers J, Morris KL, Copland A, Serpell L, Serrano L, Schymkowitz JW, Rousseau F (2010) Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods 7(3):237–242
103. Mehta R, Gantz DL, Gursky O (2003) Human plasma high-density lipoproteins are stabilized by kinetic factors. J Mol Biol 328(1):183–192
104. Mei X, Atkinson D (2011) Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization. J Biol Chem 286(44):38570–38582
105. Mendoza-Espinosa P, Montalvan-Sorrosa D, Garcia- Gonzalez V, Moreno A, Castillo R, Mas-Oliva J (2014) Microenvironmentally controlled secondary structure motifs of apolipoprotein A-I derived peptides. Mol Cell Biochem 393(1–2):99–109
106. Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B, Weisgraber KH (2000) Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry 39(38):11657–11666
107. Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, Rupp B, Weisgraber KH (2002) Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J Biol Chem 277(52):50380–50385
108. Mucchiano GI, Haggqvist B, Sletten K, Westermark P (2001) Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 193(2):270–275
109. Mulya A, Lee JY, Gebre AK, Boudyguina EY, Chung SK, Smith TL, Colvin PL, Jiang XC, Parks JS (2008) Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res 49(11):2390–2401
110. Nagao K, Hata M, Tanaka K, Takechi Y, Nguyen D, Dhanasekaran P, Lund-Katz S, Phillips MC, Saito H (2014) The roles of C-terminal helices of human apolipoprotein A-I in formation of high-density lipoprotein particles. Biochim Biophys Acta 1841(1):80–87
111. Nakajima K, Nagamine T, Fujita MQ, Ai M, Tanaka A, Schaefer E (2014) Apolipoprotein B-48: a unique marker of chylomicron metabolism. Adv Clin Chem 64:117–177
112. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8(4):222–232
113. Nguyen D, Dhanasekaran P, Nickel M, Mizuguchi C, Watanabe M, Saito H, Phillips MC, Lund-Katz S (2014) Infl uence of domain stability on the properties of human apolipoprotein E3 and E4 and mouse Apolipoprotein E. Biochemistry 53(24):4025–4033
114. Nilsson SK, Christensen S, Raarup MK, Ryan RO, Nielsen MS, Olivecrona G (2008) Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J Biol Chem 283(38):25920–25927
115. Nilsson SK, Heeren J, Olivecrona G, Merkel M (2011) Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis 219(1):15–21
116. Obici L, Franceschini G, Calabresi L, Giorgetti S, Stoppini M, Merlini G, Bellotti V (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13(4):191–205
117. O’Donnell CW, Waldispühl J, Lis M, Halfmann R, Devadas S, Lindquist S, Berger B (2011) A method for probing the mutational landscape of amyloid structure. Bioinformatics 27(13):i34–i42
118. Ohta S, Tanaka M, Sakakura K, Kawakami T, Aimoto S, Saito H (2009) Defining lipid-binding regions of human serum amyloid A using its fragment peptides. Chem Phys Lipids 162(1–2):62–68
119. Parasassi T, De Spirito M, Mei G, Brunelli R, Greco G, Lenzi L, Maulucci G, Nicolai E, Papi M, Arcovito G, Tosatto SC, Ursini F (2008) Low density lipoprotein misfolding and amyloidogenesis. FASEB J 22(7):2350–2356
120. Patel H, Bramall J, Waters H, De Beer MC, Woo P (1996) Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem J 318(Pt 3):1041–1049
121. Patel S, Chung SH, White G, Bao S, Celermajer DS (2010) The “atheroprotective” mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques. Int J Cardiol 145(2):183–187
122. Paz M, Serrano L (2004) Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci U S A 101:87–92
123. Phillips MC (2013) New insights into the determination of HDL structure by apolipoproteins. J Lipid Res 54(8):2034–2048
124. Phillips MC (2014) Molecular mechanisms of cellular cholesterol effl ux. J Biol Chem 289(35):24020–24029
125. Rached FH, Chapman MJ, Kontush A (2014) An overview of the new frontiers in the treatment of atherogenic dyslipidemias. Clin Pharmacol Ther 96(1):57–63
126. Ramella NA, Rimoldi OJ, Prieto ED, Schinella GR, Sanchez SA, Jaureguiberry MS, Vela ME, Ferreira ST, Tricerri MA (2011) Human apolipoprotein A-Iderived amyloid: its association with atherosclerosis. PLoS ONE 6(7):e22532
127. Ramella NA, Schinella GR, Ferreira ST, Prieto ED, Vela ME, Ríos JL, Tricerri MA, Rimoldi OJ (2012) Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity. PLoS ONE 7(8):e43755
128. Röcken C, Tautenhahn J, Bühling F, Sachwitz D, Vöckler S, Goette A, Bürger T (2006) Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler Thromb Vasc Biol 26:676–677
129. Rothblat GH, Phillips MC (2010) High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 21:229–238
130. Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, Hunt T, Gibbs SD, Sattianayagam PT, Pinney JH, Hawkins PN, Gillmore JD (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 179(4):1978–1987
131. Rozek A, Sparrow JT, Weisgraber KH, Cushley RJ (1999) Conformation of human apolipoprotein C-I in a lipidmimetic environment determined by CD and NMR spectroscopy. Biochemistry 38(44):14475–14484
132. Rye KA, Barter PJ (2004) Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24:421–428
133. Sabate R, Espargaro A, Graña-Montes R, Reverter D, Ventura S (2012) Native structure protects SUMO proteins from aggregation into amyloid fibrils. Biomacromolecules 13(6):1916–1926
134. Safar JG, Wille H, Geschwind MD, Deering C, Latawiec D, Serban A, King DJ, Legname G, Weisgraber KH, Mahley RW, Miller BL, Dearmond SJ, Prusiner SB (2006) Human prions and plasma lipoproteins. Proc Natl Acad Sci U S A 103(30):11312–11317
135. Sawashita J, Kametani F, Hasegawa K, Tsutsumi-Yasuhara S, Zhang B, Yan J, Mori M, Naiki H, Higuchi K (2009) Amyloid fibrils formed by selective N-, C-terminal sequences of mouse apolipoprotein A-II. Biochim Biophys Acta 1794(10):1517–1529
136. Segrest JP, Pownall HJ, Jackson RL, Glenner GG, Pollock PS (1976) Amyloid A: amphipathic helixes and lipid binding. Biochemistry 15(15):3187–3191
137. Segrest JP, De Loof H, Dohlman JG, Brouillette CG, Anantharamaiah GM (1990) Amphipathic helix motif: classes and properties. Proteins 8:103–117
138. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM (1992) The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 33(2):141–166
139. Segrest JP, Garber DW, Brouillette CG, Harvey SC, Anantharamaiah GM (1994) The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 45:303–369
140. Segrest JP, Jones MK, Dashti N (1999) N-terminal domain of apolipoprotein B has structural homology to lipovitellin and microsomal triglyceride transfer protein: a “lipid pocket” model for self-assembly of apob- containing lipoprotein particles. J Lipid Res 40(8):1401–1416
141. Segrest JP, Jones MK, De Loof H, Dashti N (2001) Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 42(9):1346–1367
142. Sehayek E, Eisenberg S (1991) Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 266(27):18259–18267
143. Shachter NS (2001) Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12(3):297–304
144. Sharma V, Forte TM, Ryan RO (2013) Infl uence of apolipoprotein A-V on the metabolic fate of triacylglycerol. Curr Opin Lipidol 24(2):153–159
145. Shewmaker F, McGlinchey RP, Wickner RB (2011) Structural insights into functional and pathological amyloid. J Biol Chem 286(19):16533–16540
146. Shih YH, Tsai KJ, Lee CW, Shiesh SC, Chen WT, Pai MC, Kuo YM (2014) Apolipoprotein C-III is an Amyloid- β-binding protein and an early marker for Alzheimer’s disease. J Alzheimers Dis 41(3):855–865
147. Silva RA, Schneeweis LA, Krishnan SC, Zhang X, Axelsen PH, Davidson WS (2007) The structure of apolipoprotein A-II in discoidal high density lipoproteins. J Biol Chem 282(13):9713–9121
148. Silva BA, Breydo L, Uversky VN (2013) Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration. Mol Neurobiol 47(2):446–459
149. Sorci-Thomas MG, Thomas MJ (2002) The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 12(3):121–128
150. Sorci-Thomas MG, Thomas MJ (2013) Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol 62(3):239–246
151. Srinivasan S, Patke S, Wang Y, Ye Z, Litt J, Srivastava SK, Lopez MM, Kurouski D, Lednev IK, Kane RS, Colón W (2013) Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2. J Biol Chem 288(4):2744–2755
152. Stewart CR, Tseng AA, Mok YF, Staples MK, Schiesser CH, Lawrence LJ, Varghese JN, Moore KJ, Howlett GJ (2005) Oxidation of low-density lipoproteins induces amyloid-like structures that are recognized by macrophages. Biochemistry 44(25):9108–9116
153. Strittmatter WJ, Saunders AM, Schmechel D, Pericak- Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to betaamyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90(5):1977–1981
154. Suri S, Heise V, Trachtenberg AJ, Mackay CE (2013) The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE ɛ2. Neurosci Biobehav Rev 37(10 Pt 2):2878–2886
155. Suzuki M, Wada H, Maeda S, Saito K, Minatoguchi S, Saito K, Seishima M (2005) Increased plasma lipidpoor apolipoprotein A-I in patients with coronary artery disease. Clin Chem 51:132–137
156. Takase H, Tanaka M, Miyagawa S, Yamada T, Mukai T (2014) Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties. Biochem Biophys Res Commun 444(1):92–97
157. Teoh CL, Griffin MD, Howlett GJ (2011a) Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell 2(2):116–127
158. Teoh CL, Pham CL, Todorova N, Hung A, Lincoln CN, Lees E, Lam YH, Binger KJ, Thomson NH, Radford SE, Smith TA, Müller SA, Engel A, Griffin MD, Yarovsky I, Gooley PR, Howlett GJ (2011b) A structural model for apolipoprotein C-II amyloid fibrils: experimental characterization and molecular dynamics simulations. J Mol Biol 405(5):1246–1266
159. Thompson MJ, Sievers SA, Karanicolas J, Ivanova MI, Baker D, Eisenberg D (2006) The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci U S A 103(11):4074–4078
160. Tian J, Wu N, Guo J, Fan Y (2009) Prediction of amyloid fibril-forming segments based on a support vector machine. BMC Bioinformatics 10(S1):S45
161. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D’Agostino RB Sr, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ (2013) High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 7(5):484–525
162. Trovato A, Seno F, Tosatto SC (2007) The PASTA server for protein aggregation prediction. Protein Eng Des Sel 20(10):521–523
163. Tsolis AC, Papandreou NC, Iconomidou VA, Hamodrakas SJ (2013) A consensus method for the prediction of ‘aggregation-prone’ peptides in globular proteins. PLoS ONE 8(1):e54175
164. Tubb MR, Silva RA, Pearson KJ, Tso P, Liu M, Davidson WS (2007) Modulation of apolipoprotein A-IV lipid binding by an interaction between the N and C termini. J Biol Chem 282(39):28385–28394
165. Tycko R (2006) Molecular structure of amyloid fibrils: insights from solid-state NMR. Q Rev Biophys 39(1):1–55
166. Tzotzos S, Doig AJ (2010) Amyloidogenic sequences in native protein structures. Protein Sci 19(2):327–348
167. Ursini F, Davies KJ, Maiorino M, Parasassi T, Sevanian A (2002) Atherosclerosis: another protein misfolding disease? Trends Mol Med 8(8):370–374
168. van der Hilst JC, Yamada T, Op den Camp HJ, van der Meer JW, Drenth JP, Simon A (2008) Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology 47(11):1651–1654
169. van der Westhuyzen DR, de Beer FC, Webb NR (2007) HDL cholesterol transport during infl ammation. Curr Opin Lipidol 18(2):147–151
170. Ventura S, Zurdo J, Narayanan S, Parreño M, Mangues R, Reif B, Chiti F, Giannoni E, Dobson CM, Aviles FX, Serrano L (2004) Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. Proc Natl Acad Sci U S A 101(19):7258–7263
171. Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol 10(3):241–252
172. Walker RG, Deng X, Melchior JT, Morris J, Tso P, Jones MK, Segrest JP, Thompson TB, Davidson WS (2014) The structure of human apolipoprotein A-IV as revealed by stable isotope-assisted cross-linking, molecular dynamics, and small angle x-ray scattering. J Biol Chem 289(9):5596–5608
173. Walsh I, Seno F, Tosatto SC, Trovato A (2014) PASTA 2.0: an improved server for protein aggregation prediction. Nucleic Acids Res 42:W301–W307 (Web Server issue)
174. Wang L, Lashuel HA, Colón W (2005) From hexamer to amyloid: marginal stability of apolipoprotein SAA2.2 leads to in vitro fibril formation at physiological temperature. Amyloid 12(3):139–148
175. Wang L, Jiang ZG, McKnight CJ, Small DM (2010) Interfacial properties of apolipoprotein B292–593 (B6.4–13) and B611–782 (B13–17). Insights into the structure of the lipovitellin homology region in apolipoprotein B. Biochemistry 49(18):3898–3907
176. Weers PM, Narayanaswami V, Choy N, Luty R, Hicks L, Kay CM, Ryan RO (2003) Lipid binding ability of human apolipoprotein E N-terminal domain isoforms: correlation with protein stability? Biophys Chem 100(1–3):481–492
177. Weinberg RB, Cook VR, Beckstead JA, Martin DD, Gallagher JW, Shelness GS, Ryan RO (2003) Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 278(36):34438–3444
178. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252(5014):1817–1822
179. Wilson LM, Mok YF, Binger KJ, Griffin MD, Mertens HD, Lin F, Wade JD, Gooley PR, Howlett GJ (2007) A structural core within apolipoprotein C-II amyloid fibrils identified using hydrogen exchange and proteolysis. J Mol Biol 366(5):1639–1651
180. Wisniewski T, Lalowski M, Golabek A, Vogel T, Frangione B (1995) Is Alzheimer’s disease an apolipoprotein E amyloidosis? Lancet 345:956–958
181. Wong K, Beckstead JA, Lee D, Weers PM, Guigard E, Kay CM, Ryan RO (2008) The N-terminus of apolipoprotein A-V adopts a helix bundle molecular architecture. Biochemistry 47(33):8768–8774
182. Wong YQ, Binger KJ, Howlett GJ, Griffin MD (2010) Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I. Proc Natl Acad Sci U S A 107(5):1977–1982
183. Wong YQ, Binger KJ, Howlett GJ, Griffin MD (2012) Identification of an amyloid fibril forming peptide comprising residues 46–59 of apolipoprotein A-I. FEBS Lett 586:1754–1758
184. Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD (1995) In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation. Scand J Immunol 41(6):570–574
185. Yao Z, Wang Y (2012) Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol 23(3):206–212
186. Zhang Z, Chen H, Lai L (2007) Identification of amyloid fibril-forming segments based on structure and residue- based statistical potential. Bioinformatics 23:2218–2225
187. Zibaee S, Makin OS, Goedert M, Serpell LC (2007) A simple algorithm locates β-strands in the amyloid fibril core of α-synuclein, Aβ, and tau using the amino acid sequence alone. Protein Sci 16:906–918